Research ExplorerPublicationsDesign and construction of targeted AAVP vectors for mammali...

Design and construction of targeted AAVP vectors for mammalian cell transduction

Standard

Design and construction of targeted AAVP vectors for mammalian cell transduction. / Hajitou, Amin; Rangel, Roberto; Trepel, Martin; Soghomonyan, Suren; Gelovani, Juri G; Alauddin, Mian M; Pasqualini, Renata; Arap, Wadih.

In: NAT PROTOC, Vol. 2, No. 3, 2007, p. 523-31.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hajitou, A, Rangel, R, Trepel, M, Soghomonyan, S, Gelovani, JG, Alauddin, MM, Pasqualini, R & Arap, W 2007, 'Design and construction of targeted AAVP vectors for mammalian cell transduction', NAT PROTOC, vol. 2, no. 3, pp. 523-31. https://doi.org/10.1038/nprot.2007.51

APA

Hajitou, A., Rangel, R., Trepel, M., Soghomonyan, S., Gelovani, J. G., Alauddin, M. M., Pasqualini, R., & Arap, W. (2007). Design and construction of targeted AAVP vectors for mammalian cell transduction. NAT PROTOC, 2(3), 523-31. https://doi.org/10.1038/nprot.2007.51

Vancouver

Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. NAT PROTOC. 2007;2(3):523-31. https://doi.org/10.1038/nprot.2007.51

Bibtex

@article{76403cc30c034414b0b04148168241bd,
title = "Design and construction of targeted AAVP vectors for mammalian cell transduction",
abstract = "Bacteriophage (phage) evolved as bacterial viruses, but can be adapted to transduce mammalian cells through ligand-directed targeting to a specific receptor. We have recently reported a new generation of hybrid prokaryotic-eukaryotic vectors, which are chimeras of genetic cis-elements of recombinant adeno-associated virus and phage (termed AAVP). This protocol describes the design and construction of ligand-directed AAVP vectors, production of AAVP particles and the methodology to transduce mammalian cells in vitro and to target tissues in vivo after systemic administration. Targeted AAVP particles are made in a two-step process. First, a ligand peptide of choice is displayed on the coat protein to generate a targeted backbone phage vector. Then, a recombinant AAV carrying a mammalian transgene cassette is inserted into an intergenomic region. High-titer suspensions (approximately 10(10)-10(11) transducing units per microl) can be produced within 3 days after vector construction. Transgene expression by targeted AAVP usually reaches maximum levels within 1 week.",
keywords = "Animals, Bacteriophages, DNA Primers, Dependovirus, Genetic Therapy, Genetic Vectors, Luciferases, Mice, Transduction, Genetic, Transgenes, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.",
author = "Amin Hajitou and Roberto Rangel and Martin Trepel and Suren Soghomonyan and Gelovani, {Juri G} and Alauddin, {Mian M} and Renata Pasqualini and Wadih Arap",
year = "2007",
doi = "10.1038/nprot.2007.51",
language = "English",
volume = "2",
pages = "523--31",
journal = "NAT PROTOC",
issn = "1754-2189",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Design and construction of targeted AAVP vectors for mammalian cell transduction

AU - Hajitou, Amin

AU - Rangel, Roberto

AU - Trepel, Martin

AU - Soghomonyan, Suren

AU - Gelovani, Juri G

AU - Alauddin, Mian M

AU - Pasqualini, Renata

AU - Arap, Wadih

PY - 2007

Y1 - 2007

N2 - Bacteriophage (phage) evolved as bacterial viruses, but can be adapted to transduce mammalian cells through ligand-directed targeting to a specific receptor. We have recently reported a new generation of hybrid prokaryotic-eukaryotic vectors, which are chimeras of genetic cis-elements of recombinant adeno-associated virus and phage (termed AAVP). This protocol describes the design and construction of ligand-directed AAVP vectors, production of AAVP particles and the methodology to transduce mammalian cells in vitro and to target tissues in vivo after systemic administration. Targeted AAVP particles are made in a two-step process. First, a ligand peptide of choice is displayed on the coat protein to generate a targeted backbone phage vector. Then, a recombinant AAV carrying a mammalian transgene cassette is inserted into an intergenomic region. High-titer suspensions (approximately 10(10)-10(11) transducing units per microl) can be produced within 3 days after vector construction. Transgene expression by targeted AAVP usually reaches maximum levels within 1 week.

AB - Bacteriophage (phage) evolved as bacterial viruses, but can be adapted to transduce mammalian cells through ligand-directed targeting to a specific receptor. We have recently reported a new generation of hybrid prokaryotic-eukaryotic vectors, which are chimeras of genetic cis-elements of recombinant adeno-associated virus and phage (termed AAVP). This protocol describes the design and construction of ligand-directed AAVP vectors, production of AAVP particles and the methodology to transduce mammalian cells in vitro and to target tissues in vivo after systemic administration. Targeted AAVP particles are made in a two-step process. First, a ligand peptide of choice is displayed on the coat protein to generate a targeted backbone phage vector. Then, a recombinant AAV carrying a mammalian transgene cassette is inserted into an intergenomic region. High-titer suspensions (approximately 10(10)-10(11) transducing units per microl) can be produced within 3 days after vector construction. Transgene expression by targeted AAVP usually reaches maximum levels within 1 week.

KW - Animals

KW - Bacteriophages

KW - DNA Primers

KW - Dependovirus

KW - Genetic Therapy

KW - Genetic Vectors

KW - Luciferases

KW - Mice

KW - Transduction, Genetic

KW - Transgenes

KW - Journal Article

KW - Research Support, N.I.H., Extramural

KW - Research Support, Non-U.S. Gov't

KW - Research Support, U.S. Gov't, Non-P.H.S.

U2 - 10.1038/nprot.2007.51

DO - 10.1038/nprot.2007.51

M3 - SCORING: Journal article

C2 - 17406616

VL - 2

SP - 523

EP - 531

JO - NAT PROTOC

JF - NAT PROTOC

SN - 1754-2189

IS - 3

ER -